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Abstract 
Aims: Patients with heart failure (HF) and concomitant diabetes carry a poor prognosis. In 
this post-hoc subgroup analysis, we compared the outcomes of patients with and without 
diabetes randomized in EchoCRT. 
 
Methods and Results: EchoCRT randomized patients with a QRS duration <130 msec and 
echocardiographic evidence of left ventricular dyssynchrony to CRT-ON vs. CRT-OFF 
following device implantation. At study entry, 328 patients (40.5%) had diabetes. The 
primary outcome (all-cause death or first hospitalization for worsening HF) occurred more 
frequently in patients with vs. without diabetes (32.6% vs. 23%, p=0.003). A significant 
treatment interaction was observed for the primary outcome indicating a higher risk for CRT-
ON vs. –OFF in patients without (26.5% vs. 19.8%, hazard ratio (HR) 1.58; 95% confidence 
interval (CI) 1.08-2.31) vs. with diabetes (31.4% vs. 34%; HR 0.86; 95% CI 0.58 – 1.27; p 
interaction = 0.041). This effect was mainly driven by a lower rate in HF hospitalizations, but 
was only of borderline significance after multivariate adjustment (p=0.063). The most 
pronounced effect was observed in patients with non-ischemic cardiomyopathy, where a 
significantly reduced risk to reach the primary endpoint for CRT-ON vs. –OFF was observed 
in patients with (HR 0.27, p=0.003) vs. without diabetes (HR 1.79, p=0.038; p interaction 
0.005). No treatment interaction by diabetes diagnosis was found for mortality endpoints. 
 
Conclusion: In EchoCRT, heart failure patients with a narrow QRS complex and coexisting 
diabetes demonstrated a signal for less harm of CRT compared to patients without diabetes, 
which was driven by differences in HF hospitalizations. 
 
Key words: Heart Failure; Cardiac Resynchronization Therapy; Narrow QRS; Diabetes. 
ClinicalTrials.gov Identifier: NCT00683696  
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Introduction 
 
Patients with diabetes mellitus have an elevated risk for cardiac events, including the 
development of heart failure. Conversely, the prognosis of patients with symptomatic heart 
failure and concomitant diabetes is dire, with both morbidity and mortality well in excess of 
that observed in patients without diabetes.1-3 Cardiac resynchronization therapy (CRT) 
reduces morbidity and mortality in patients with symptomatic heart failure with reduced 
ejection fraction and a wide QRS complex,4-7 and has become standard of care in the 
treatment of such patients.8 Patients with diabetes have been demonstrated to derive at least a 
similar benefit from CRT than patients without diabetes based on several subanalyses of large 
randomized clinical trials.9-12 In the same way, a substantial benefit of CRT was observed for 
diabetes patients in real world registries.13, 14 
Based on the observation that a substantial proportion of heart failure patients presents 
with a narrow QRS complex,15 the EchoCRT trial was conducted to assess the effect of CRT 
in patients with a QRS duration ≤ 130 msec who present with echocardiographic evidence of 
left ventricular dyssynchrony. The trial was terminated early due to futility, and demonstrated 
a relative increase in all-cause mortality of 81% with CRT in this patient population.16 
Evidence on the effect of CRT in heart failure patients with diabetes and a narrow QRS 
complex is scarce. While a more beneficial response appears possible as extrapolated from 
data on diabetes patients with a wide QRS complex,11, 17 patients with diabetes are known to 
be more susceptible to arrhythmias and may thus be at higher risk in the context of a narrow 
QRS complex and biventricular pacing.18 This post-hoc subgroup analysis was therefore 
performed to assess the efficacy and safety of CRT in patients with and without diabetes 
randomized in EchoCRT. 
 
 4 / 31 
Methods 
 
Study design and conduct 
EchoCRT was an investigator-initiated, multicenter, international, randomized clinical 
trial. The results of the main trial including the methodology have been reported.16 Patients 
were eligible if they were on optimized medical heart failure therapy, had a standard 
indication for an implantable cardioverter–defibrillator (ICD), were suffering from 
symptomatic heart failure (New York Heart Association (NYHA) class III or IV), had a left 
ventricular ejection fraction (EF) ≤ 35%, a QRS duration of < 130 msec, a left ventricular 
end-diastolic diameter (LVEDD) of ≥ 55 mm, and echocardiographic evidence of left 
ventricular dyssynchrony as previously defined.16 After implantation of a Biotronik Lumax 
HF-T CRT-D system, patients were randomly assigned in a 1:1 ratio to have cardiac 
resynchronization turned on (CRT-ON group) or off (CRT-OFF control group). While 
physicians involved in the device implantation and follow-up were aware of the study-group 
assignments, heart-failure physicians, patients, and study personnel completing the follow-up 
assessments were not. The trial was designed by the executive committee and was sponsored 
by Biotronik with support for echocardiographic training and software provided by GE 
Healthcare. Diagnosis of diabetes was made at the discretion of the local study site 
investigators at enrollment into the trial. In cases where diagnosis of diabetes was unclear 
(n=13), diagnosis was made by the central study team according to available medical reports 
and concomitant medication. 
 
Endpoints 
The primary combined efficacy outcome consisted of the combination of death from 
any cause or first hospitalization for worsening heart failure.16 The pre-specified secondary 
outcomes included time to first hospitalization for worsening heart failure; all-cause 
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mortality; cardiovascular mortality; and cardiovascular hospitalization.16 The primary safety 
outcome was freedom from CRT-D related complications at 6 months in the implanted 
population.  
 
Statistical analysis  
All study results were independently analyzed at the Robertson Centre for Biostatistics 
at the University of Glasgow. All analyses were performed by intention-to-treat. Baseline 
characteristics were compared with the use of chi-square (or Fisher’s exact) and two-sample t-
tests for categorical and continuous variables, respectively. Hazard ratios (HRs) for CRT-OFF 
and CRT-ON (with 95% confidence intervals) were calculated with the Cox proportional 
hazards models for patients with vs. without diabetes, stratified for country. In addition, a 
multivariable Cox proportional hazards model was performed to account for differences 
across randomized treatment groups in baseline characteristics between patients with and 
without diabetes (age, gender, sitting systolic blood pressure, body mass index, ischemic 
cardiomyopathy, history of coronary artery bypass graft and chronic kidney disease). 
Interactions between patients with and without diabetes (CRT=ON and CRT=OFF) were 
tested for in Cox models that included diabetes and treatment main effects and interaction 
terms. Time to event curves were estimated with the use of the Kaplan-Meier method. All 
tests were two-sided; a p value <0.05 was considered significant. 
 
Results 
 
Baseline characteristics 
Patient characteristics at trial entry are shown in Table 1. Out of 809 randomized 
patients, 328 (40.5%) had a diagnosis of diabetes at baseline. In 3 patients, the status of 
diabetes could not be definitely assessed. Of the 328 patients with diabetes at baseline, 172 
 6 / 31 
(52.4%) were randomized to CRT-ON and 156 (47.6%) to CRT-OFF. Of the 478 patients 
without diabetes, 230 (48.1%) were randomized to CRT-ON and 248 (51.9%) to CRT-OFF. 
Baseline characteristics by group allocation and diabetes status are shown in Supplementary 
Table 1. There was no significant difference in group allocation to CRT-ON between patients 
with vs. without diabetes (p=0.228). Patients with diabetes were older, had a higher average 
body mass index (BMI), more frequently had hypertension, chronic kidney disease, thyroid 
disease, and more frequently had underlying ischemic cardiomyopathy and prior coronary 
artery bypass grafting. They achieved a shorter walking distance, reported worse heart failure-
related quality of life and were more frequently treated with diuretics, nitrates, statins and 
aspirin.  
 
Outcomes in patients with vs. without diabetes 
Outcomes and event rates in patients with and without diabetes are summarized in 
Table 2. The primary combined outcome (death from any cause or first hospitalization for 
worsening heart failure) occurred more frequently in patients with vs. without diabetes 
(32.6% vs. 23.0%, p=0.008 in fully adjusted analysis). Patients with vs. without diabetes also 
had a higher event rates for heart failure hospitalizations (28.1% vs. 20.1%, p=0.001 all-cause 
mortality (11.9% vs. 6.7%, p=0.03 in fully adjusted analysis) and non-cardiovascular 
infections (17.1% vs. 9.8%, p=0.002). In contrast, there was no significant difference in the 
primary safety outcome of freedom from complications related to the CRT-D system at 6 
months between patients with vs. without diabetes (91.2% vs. 88.1% respectively, p=0.17 in 
unadjusted analysis; Table 3). Multivariate adjustment did not significantly alter this result. 
 
Efficacy of CRT in patients with vs. without diabetes 
A significant treatment interaction was observed for the primary outcome indicating a 
higher risk for CRT-ON vs. –OFF in patients without (26.5% vs. 19.8%; hazard ratio (HR) 
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1.58; 95% confidence interval (CI) 1.08 – 2.31) vs. with diabetes (31.4% vs. 34.0%, HR 0.86; 
95% CI 0.58 – 1.27; p interaction =0.041, Figs. 1A & 2). This effect was mainly driven by a 
significant treatment interaction for worsening heart failure hospitalizations, for which a 
higher risk for CRT-ON vs. –OFF was observed in patients without diabetes (23.0% vs. 
17.3%; HR 1.57 (95% CI 1.05 – 2.35) compared to with diabetes (26.2% vs. 30.1%; HR 0.80 
(95% CI 0.53 – 1.22); p interaction 0.035). Similarly, cardiovascular hospitalizations were 
more frequent in CRT-ON vs. –OFF in patients without as compared to with diabetes (p 
interaction = 0.029). The interaction by diabetes status for the primary endpoint remained 
borderline significant (p interaction=0.063) after adjustment for baseline parameters (Fig. 3).  
An exploratory post-hoc analysis revealed that patients with non-ischemic 
cardiomyopathy were the main driver of this effect. Of the 374 patients with non-ischemic 
cardiomyopathy, 125 had a diagnosis of diabetes of which 64 (51.2%) were randomized to 
CRT-ON. A significantly reduced risk to reach the primary efficacy endpoint for CRT-ON vs. 
–OFF was observed in patients with (25.01% vs. 32.8%, HR 0.27 (95% CI 0.11 – 0.65), 
p=0.005) as compared to without diabetes (29.2% vs. 17.1%; HR 1.79 (95% CI 1.03 – 3.11), 
p=0.04) in patients with non-ischemic cardiomyopathy after multivariate adjustment (p 
interaction 0.005). In contrast, no difference in events was observed for CRT-ON vs. –OFF in 
ischemic cardiomyopathy (HR 1.09 (95% CI 0.67 – 1.78), p=0.72) vs. HR 1.10 (95% CI 0.62 
– 1.97), p=0.74) for diabetes vs. non-diabetes patients, respectively, after multivariate 
adjustment (p interaction 0.96).   
There was no treatment interaction for all-cause mortality (Fig 1B), as well as heart 
failure and cardiovascular mortality in patients with vs. without diabetes, both unadjusted 
(Fig. 2) and after adjustment for baseline differences (Fig. 3). Indeed, in the fully adjusted 
analysis, the hazard ratio for all-cause mortality in the CRT-ON vs. CRT-OFF group was 1.58 
(95% CI 0.78 – 3.20) in patients with diabetes and 1.60 (95% CI 0.77 – 3.32) in patients 
without diabetes (p interaction 0.98). 
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Discussion 
 
The current subgroup analysis of EchoCRT reveals three important key findings. First, 
in this population of heart failure patients with a narrow QRS complex and echocardiographic 
signs of dyssynchrony, patients with diabetes show less evidence of harm by CRT than 
patients without diabetes. Second, these differences in the primary outcome are primarily 
driven by differences in heart failure hospitalizations. Third, although patients with diabetes 
had an overall higher morbidity and mortality, no significant differences in CRT-D- or 
implant-related complications were seen between patients with or without diabetes. 
 The presence of diabetes poses a challenge in the everyday treatment of patients with 
heart failure, with a worse prognosis observed in a multitude of clinical trials and registries.1-3 
Conversely, patients with diabetes enrolled in the pivotal CRT trials generally fared worse 
than those without diabetes. In CARE-HF, the risk of all-cause mortality was increased by 
30% in patients with as compared to without diabetes by the end of the extension period.9 
Also in MADIT-CRT patients with diabetes more frequently reached the primary endpoint as 
compared to those without diabetes (26.6% vs. 18%).11 In COMPANION, a numerically 
increased risk for mortality and / or HF hospitalization was observed in patients with diabetes, 
which was not significant after multivariate adjustment.10 Our data demonstrating an 
increased risk for both HF hospitalization and all-cause mortality in diabetes patients are 
hence in line with the results from previous landmark trials in diabetes patients receiving 
CRT. 
 In those same trials, patients with diabetes derived at least a similar if not greater 
benefit from CRT than those without diabetes. In CARE-HF, patients randomized to CRT 
pacemaker vs. optimal medical therapy had a similar reduction in all endpoints independent of 
concomitant diabetes.9 In COMPANION, a reduction of all major morbidity and/or mortality 
endpoints was observed in the combined cohort of diabetes patients receiving CRT-P or CRT-
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D compared with diabetes patients on optimal medical therapy.10 In MADIT-CRT, a 
consistent effect of CRT-D as compared to ICD therapy was observed in patients with and 
without diabetes, with a suggestion of an earlier and greater benefit from CRT-D in patients 
with diabetes.11 Importantly in the latter trial, the benefit of CRT appear larger in diabetes 
patients with non-ischemic cardiomyopathy than in ischemic cardiomyopathy, although there 
was no statistically significant interaction (HR 0.30 vs. HR 0.59; p int = 0.10).19 This 
observation led us to further post-hoc dissect the effect of CRT in patients with diabetes and 
non-ischemic cardiomyopathy. In line with MADIT-CRT, CRT was associated with a 76% 
reduced risk for the primary composite endpoint in patients with non-ischemic 
cardiomyopathy and coexisting diabetes in our study, which is almost identical to the 70% 
relative risk reduction observed in MADIT-CRT.19 In contrast, a 79% increased relative risk 
for the primary outcome with CRT was observed in patients with non-ischemic 
cardiomyopathy without diabetes.  
The mechanism underlying this differential effect is presently unclear, but may be 
related to a different pathophysiology of diabetic cardiomyopathy in patients with vs. without 
clinically apparent coronary artery disease. Indeed, patients with diabetes may develop overt 
heart failure in the absence of coronary artery disease,20 which may be related to a variety of 
pathophysiological changes including metabolic disturbances, myocardial fibrosis, small 
vessel disease, cardiac autonomic neuropathy and insulin resistance.21 In the Framingham 
Study cohort, patients with diabetes had increased LV mass and wall thickness on 
echocardiography, which remains significant even after adjusting for confounding factors.22 
Whether and how these factors may be involved in the differential effect observed in 
EchoCRT currently remains elusive and will require further study. The premature termination 
of the trial as well as the absolute low number of events precludes further meaningful sub-
subanalysis within the group of non-ischemic diabetic patients, including investigation of 
individuals who potentially profit more of CRT such as women.  
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 The trend towards less harm in the primary composite endpoint in diabetes patients 
randomized to CRT-ON was primarily driven by differences in heart failure hospitalizations. 
No difference in all-cause mortality for CRT-ON vs. –OFF was observed among patients with 
and without diabetes. This is in contrast to MADIT-CRT where CRT reduced all-cause 
mortality to a significantly higher extent in insulin-treated diabetes patients compared to 
orally treated diabetes patients and patients without diabetes in a recent subanalysis of the 
trial.11, 17 
The reasons for the differential effect of CRT between diabetes patients with a narrow 
and a wide QRS complex are unclear. On the one hand, several mechanisms for a worse 
outcome in diabetes patients receiving CRT may be conceivable, such as myocardial fibrosis, 
microvascular dysfunction, lipid accumulation, altered autonomic tone, or side-effects of anti-
glycemic drugs, hypoglycemia in particular.23-25 Combined these phenomena may make 
patients with diabetes more prone to any potential pro-arrhythmogenic effect of CRT in the 
context of a narrow QRS complex. On the other hand, CRT has been shown to improve the 
metabolomic profile of heart failure patients and CRT-mediated restoration of glucose 
metabolism may be especially advantageous for insulin-treated diabetes patients.26, 27 Finally, 
based on a small study, patients with diabetes may have more pronounced echocardiographic 
dyssynchrony despite similar QRS duration than non-diabetic patients, making them 
potentially more amendable to cardiac resynchronization.28  However, no significant 
differences in the extent of echocardiographic dyssynchrony were found at baseline or at 6 
months in patients with as compared to without diabetes in EchoCRT29, although the 
dyssynchrony entry criteria may have created a bias in this regard. In addition, none of these 
observations readily explain the different response between EchoCRT and MADIT-CRT 
patients, and further investigations are required to elucidate the underlying mechanisms 
involved.  
 
 11 / 31 
Limitations 
 
Any subgroup analysis, including the current investigation of patients with diabetes 
should by definition be interpreted as hypothesis generating. According to the current 2016 
European Society of Cardiology heart failure guidelines CRT is not recommended for patients 
with a QRS duration < 130ms, independent of the presence or absence of diabetes.30 As 
EchoCRT demonstrated an excess of mortality of patients randomized to CRT, the trial was 
stopped prematurely, thus reducing the statistical power of any subgroup analysis. As such, 
for some analyses event rates were relatively low, particularly when assessing the sub-
subgroup of non-ischemic vs. ischemic cardiomyopathy. The trial excluded patients with 
atrial fibrillation and advanced renal insufficiency, hence selection bias in the diabetes 
patients included in the study cannot be excluded. Glucose and HbA1c levels were not 
available at the time of diagnosis or during follow-up. As a result, misclassification may have 
occurred in some patients. Furthermore, no sub-subgroup analyses could be performed 
according to glycemic control (e.g. low vs. high HbA1c). Also, information on the type of 
diabetes was not available. Given the age and characteristics of the study population, it is very 
likely that the majority of patients had a diagnosis of type 2 diabetes. Finally, detailed 
information on the antidiabetic treatments were not available and thus no analyses by oral and 
non-oral antidiabetic medications (i.e. insulin use) could be performed. 
 
Conclusion 
 
In the present subgroup analysis of EchoCRT on patients with heart failure and a 
narrow QRS complex, a signal for less harm of CRT was found in patients with vs. without 
diabetes. This effect was mainly observed in patients with non-ischemic cardiomyopathy and 
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was driven by differences in heart failure hospitalizations without significant differences in 
mortality. These results, together with the consistent data from the other large CRT trials, may 
help clinical decision making in the “grey zone” of CRT indications. Further studies are 
required to analyze the underlying mechanisms of these results in order to maximize the 
benefit of CRT in this difficult to treat patient population.  
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Tables 
Table 1: Baseline characteristics  
Variable Diabetes (n=328) No diabetes (n=478) P-value 
Assigned to CRT=ON 172 (52.4%) 230 (48.1%) 0.228 
Age (years) 59.7 (10.8) 56.8 (13.8) 0.001 
Males 231 (70.4%) 353 (73.9%) 0.285 
QRS width (site; msec) 105.3 (12.5) 105.2 (13.1) 0.843 
QRS width (core; msec) 105.2 (11.78) 106.2 (13.1) 0.291 
6-minute walking distance (m) 291.8 (112.8) 348.5 (119.9) <0.001 
Quality of life score (MLHFQ) 53.7 (24.1) 49.4 (24.2) 0.014 
BNP (pg/ml) 229.0 (104.0, 574.0) 268.0 ( 84.0, 540.0) 0.988 
NT-proBNP (pg/ml) 1054.0 (449.5, 2221.0) 1158.0 (539.0, 2356.0) 0.463 
Sitting SBP (mmHg) 119.1 (19.4) 118.6 (19.5) 0.727 
Sitting DBP (mmHg) 72.3 (11.9) 73.2 (12.0) 0.300 
BMI (kg/m2) 32.6 (15.1) 29.7 ( 9.5) <0.001 
Ischemic cardiomyopathy 203 (61.9%) 228 (47.8%) <0.001 
MI > 3 months ago 143 (43.6%) 179 (37.5%) 0.080 
PCI > 3 months ago 129 (39.3%) 158 (33.1%) 0.068 
CABG more than 3 months ago 75 (22.9%) 75 (15.7%) 0.010 
Hypertension 264 (81.0%) 267 (56.5%) <0.001 
Congenital heart disease 2 (0.6%) 14 (3.0%) 0.019 
Prior ischemic stroke or TIA 47 (14.5%) 48 (10.1%) 0.061 
Chronic lung disease 60 (18.5%) 88 (18.5%) 0.982 
Chronic kidney disease 69 (21.2%) 39 (8.2%) <0.001 
Thyroid disease 36 (11.0%) 33 (6.9%) 0.043 
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LVEF Biplane (%) 27.2 (5.2) 26.9 (5.8) 0.466 
LV end diastolic dimeter (mm) 65.5 (7.0) 67.0 (7.8) 0.005 
LV lead location optimal 207 (79.0%) 314 (79.7%) 0.831 
Qualified by TDI and/or radial dyssynchrony 0.437 
Tissue Doppler imaging only 85 (25.9%) 116 (24.3%) 
Radial strain only 81 (24.7%) 104 (21.8%) 
Tissue Doppler imaging and 
radial strain 
162 (49.4%) 257 (53.9%) 
NYHA classification 
  
* 
I 0 ( 0.00%) 5 (1.1%) 
II 7 (2.1%) 12 (2.5%) 
III 310 (94.5%) 447 (93.5%) 
IV 11 (3.4%) 14 (2.9%) 
Concomitant medication 
  
  
ACE inhibitor or ARB 309 (94.2%) 456 (95.4%) 0.450 
Aldosterone antagonist 189 (57.6%) 295 (61.7%) 0.244 
Beta-blocker 321 (97.9%) 458 (95.8%) 0.112 
Diuretic agent 295 (89.9%) 400 (83.7%) 0.011 
Nitrate 97 (29.6%) 90 (18.8%) <0.001 
Antidiabetic medication 283 (86.3%) 5 (1.1%) <0.001 
Statin 254 (77.4%) 294 (61.5%) <0.001 
Aspirin 235 (71.7%) 294 (61.5%) 0.003 
Anticoagulant 75 (22.9%) 136 (28.5%) 0.076 
Amiodarone 28 (8.5%) 43 (9.0%) 0.821 
Digoxin 65 (19.8%) 84 (17.6%) 0.420 
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Antiarrhythmic drugs 84 (25.6%) 124 (25.9%) 0.916 
 
For categorical variables number and percentage are reported; for continuous variables mean 
and standard deviation are reported (except for BNP and NT-proBNP where median and 
inter-quartile range are presented). * p-value not reported due to small numbers.  
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; 
BMI, body mass index; BNP, brain natriuretic peptide, CRT, cardiac resynchronization 
therapy; BMI, body mass index; DBP, diastolic blood pressure, LV, left ventricular; LVEF, 
left ventricular ejection fraction; MI, myocardial infarction; MLHFQ, Minnesota Living with 
Heart Failure Questionnaire; NYHA, New-York Heart Association; PCI, percutaneous 
coronary intervention; SBP, systolic blood pressure; TIA, transient ischemic attack 
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Table 2: Efficacy outcomes in patients with and without diabetes 
 
Endpoint 
Diabetes 
(n=328) 
No diabetes 
(n=478) 
HR (95% 
CI)* 
P-
value 
Fully adjusted 
HR (95% 
CI)** 
P-
value 
Death or WHF 
hospitalization 
107 (32.6%) 110 (23.0%) 
1.66 ( 1.26, 
2.17)  
<0.001 
1.48 ( 1.10, 
1.97)  
 0.008 
WHF hospitalization 
92 (28.1%) 96 (20.1%) 
1.61 ( 1.20, 
2.16)  
0.001 
1.45 ( 1.06, 
1.98)  
0.020 
All-cause mortality 
39 (11.9%) 32 (6.7%) 
2.08 ( 1.29, 
3.36)  
0.003 
1.79 ( 1.06, 
3.03)  
0.030 
Cardiovascular mortality 
33 (10.1%) 21 (4.4%) 
2.80 ( 1.59, 
4.92)  
<0.001 
2.41 ( 1.30, 
4.45)  
0.005 
Heart failure mortality 
16 (4.9%) 11 (2.3%) 
2.69 ( 1.22, 
5.97)  
 0.015 
2.45 ( 1.03, 
5.78)  
0.042 
Cardiovascular 
hospitalization 
121 (36.9%) 162 (33.9%) 
1.24 ( 0.97, 
1.57)  
0.081 
1.09 ( 0.84, 
1.40)  
0.529 
 
* adjusted for country (p-value from Wald test).  ** adjusted for country, randomized 
treatment group, age, gender, sitting systolic blood pressure, body mass index, ischemic 
cardiomyopathy, history of coronary artery bypass graft and history of chronic kidney disease 
(p-value from Wald test). Abbreviations: WHF, worsening heart failure 
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Table 3: Primary safety outcome (freedom from complications related to the CRT-D 
system at 6 months) in patients with and without diabetes 
 
Endpoint Diabetes 
(n=328) 
No Diabetes 
(n=478) 
P-value 
Subjects (%) Complication-Free 
CRT-D system 306 (93.3%) 432 (90.4%) 0.15 
Implant procedure 322 (98.2%) 467 (97.7%) 0.65 
Other 327 (99.7%) 477 (99.8%)  0.79 
Any of the above 299 (91.2%) 421 (88.1%) 0.17 
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Supplementary Table S1: Baseline characteristics by diabetes and randomization group 
Variable 
Diabetes, 
CRT=ON  
(n=172) 
Diabetes, 
CRT=OFF 
(n=156) 
No diabetes, 
CRT=ON 
(n=230) 
No diabetes, 
CRT=OFF 
(n=248) 
Age (years) 59.6 (10.5) 59.7 (11.2) 56.0 (14.3) 57.4 (13.3) 
Males 128 (74.4%) 103 (66.0%) 165 (71.7%) 188 (75.8%) 
QRS width (site) 105.1 (12.3) 105.6 (12.7) 104.9 (13.7) 105.4 (12.7) 
QRS width (core) 105.1 (12.0) 105.3 (11.5) 106.8 (13.8) 105.6 (12.5) 
Walking distance (m) 299.0 (113.7) 283.6 (111.7) 350.2 (117.9) 346.9 (121.9) 
Quality of life score 54.4 (24.7) 52.9 (23.5) 49.0 (23.9) 49.8 (24.6) 
BNP (pg/ml) 213.0 (108.0, 
498.0) 
276.0 (100.0, 
683.0) 
266.5 (74.0, 
626.0) 
271.0 (106.0, 
500.5) 
NT-proBNP (pg/ml) 1230.0 (472.0, 
2520.0) 
927.0 (410.0, 
1997.0) 
1335.0 (556.0, 
2579.0) 
1071.5 (533.5, 
2080.5) 
Sitting SBP (mmHg) 118.3 (19.5) 120.0 (19.3) 117.0 (19.9) 120.1 (19.0) 
Sitting DBP (mmHg) 72.1 (11.4) 72.4 (12.5) 73.1 (12.6) 73.2 (11.4) 
BMI (kg/m2) 32.1 (15.4) 33.2 (14.9) 29.4 (7.7) 29.9 (10.9) 
Ischemic cardiomyopathy 108 (62.8%) 95 (60.9%) 110 (47.8%) 118 (47.8%) 
Non-ischemic cardiomyopathy 64 (37.2%) 61 (39.1%) 120 (52.2%) 129 (52.0%) 
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Myocardial infarction more 
than 3 months ago 
80 (46.5%) 63 (40.4%) 87 (37.8%) 92 (37.1%) 
Percutaneous coronary 
intervention more than 3 
months ago 
74 (43.0%) 55 (35.3%) 82 (35.7%) 76 (30.7%) 
CABG more than 3 months 
ago 
44 (25.6%) 31 (19.9%) 33 (14.4%) 42 (16.9%) 
Hypertension 138 (80.7%) 126 (81.3%) 122 (53.7%) 145 (58.9%) 
Congenital heart disease 1 (0.6%) 1 (0.7%) 5 (2.2%) 9 (3.7%) 
Prior ischemic stroke or TIA 24 (14.1%) 23 (14.8%) 24 (10.5%) 24 (9.8%) 
Chronic lung disease 30 (17.5%) 30 (19.5%) 39 (17.1%) 49 (19.8%) 
Chronic kidney disease 40 (23.5%) 29 (18.7%) 26 (11.3%) 13 (5.3%) 
Thyroid disease 14 (8.2%) 22 (14.1%) 19 (8.3%) 14 (5.7%) 
LVEF Biplane (%) 27.1 (5.5) 27.3 (4.8) 27.0 (5.8) 26.8 (5.8) 
LV end diastolic dimeter (mm) 65.9 (6.9) 65.1 (7.2) 67.3 (8.1) 66.8 (7.5) 
LV lead location optimal 102 (75.6%) 105 (82.7%) 155 (83.3%) 159 (76.4%) 
Qualified by TDI and/or radial dyssynchrony 
Tissue Doppler imaging only 41 (23.8%) 44 (28.2%) 54 (23.6%) 62 (25.0%) 
Radial strain only 40 (23.3%) 41 (26.3%) 45 (19.7%) 59 (23.8%) 
Tissue Doppler imaging and 91 (52.9%) 71 (45.5%) 130 (56.8%) 127 (51.2%) 
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radial strain 
NYHA classification      
I 0 (0.0%) 0 (0.0%) 2 (0.9%) 3 (1.2%) 
II 5 (2.9%) 2 (1.3%) 2 (0.9%) 10 (4.0%) 
III 162 (94.2%) 148 (94.9%) 221 (96.1%) 226 (91.1%) 
IV 5 (2.9%) 6 (3.9%) 5 (2.17%) 9 (3.6%) 
Concomitant medication      
ACE inhibitor or ARB 163 (94.8%) 146 (93.6%) 218 (94.8%) 238 (96.0%) 
Aldosterone antagonist 101 (58.7%) 88 (56.4%) 145 (63.0%) 150 (60.5%) 
Beta-blocker 167 (97.1%) 154 (98.7%) 218 (94.8%) 240 (96.8%) 
Diuretic agent 152 (88.4%) 143 (91.7%) 192 (83.5%) 208 (83.9%) 
Nitrate 52 (30.2%) 45 (28.9%) 45 (19.6%) 45 (18.2%) 
Antidiabetic medication 146 (84.9%) 137 (87.8%) 2 (0.9%) 3 (1.2%) 
Statin 135 (78.5%) 119 (76.3%) 144 (62.6%) 150 (60.5%) 
Aspirin 131 (76.2%) 104 (66.7%) 134 (58.3%) 160 (64.5%) 
Anticoagulant 38 (22.1%) 37 (23.7%) 65 (28.3%) 71 (28.6%) 
Amiodarone 14 (8.1%) 14 (9.0%) 28 (12.2%) 15 (6.1%) 
Digoxin 35 (20.4%) 30 (19.2%) 45 (19.6%) 39 (15.7%) 
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Antiarrhythmic drugs 43 (25.0%) 41 (26.3%) 67 (29.1%) 57 (23.0%) 
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Figures 
 
Figure 1: Kaplan–Meier Estimates for primary outcome and all-cause mortality events, 
stratified by diabetes.  
Kaplan–Meier curves for (A) the primary composite efficacy outcome of death from any 
cause or hospitalization for heart failure and (B) death from any cause in patients with and 
without diabetes, randomized to CRT-ON and CRT-OFF.  
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Figure 2: Effect of CRT in patients with (lower, red) and without (upper, black) 
diabetes.  
Hazard ratio (HR; 95% confidence interval (CI)) adjusted for country and p-value from Wald 
test are presented. Abbreviations: WHF, worsening heart failure. 
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Figure 3: Effect of CRT in patients with (lower, red) and without (upper, black) diabetes 
after multivariable adjustment 
Hazard ratio (HR; 95% confidence interval (CI)) adjusted for country, age, gender, sitting 
systolic blood pressure, body mass index, ischemic cardiomyopathy, history of coronary 
artery bypass graft and history of chronic kidney disease (p-value from Wald test). 
Abbreviations: WHF, worsening heart failure. 
 
